Market Overview - U.S. equities ended the first full trading week of 2026 positively, with major benchmarks like the S&P 500 and Dow Jones Industrial Average reaching new record highs, influenced by geopolitical events and a mixed December jobs report [2] - Investors shifted focus from mega-cap technology stocks to cyclical sectors, particularly energy and defense, following a significant U.S. military operation in Venezuela and expectations of increased crude supply [2][3] Sector Performance - Energy and defense stocks led the market gains, with oil-related equities rising due to optimism about Venezuela's potential to supply crude oil to U.S. markets, while defense contractors benefited from plans for a larger Pentagon budget in 2027 [3] - Smaller defense contractors outperformed the broader market, indicating a shift in market leadership influenced by geopolitical factors [3] Economic Data - The December jobs report indicated slower than expected payroll growth but a lower unemployment rate, alleviating some investor concerns regarding labor market stress [4] - Mixed sentiments around inflation and labor conditions suggested that the Federal Reserve may maintain steady interest rates in the near term [4] Notable Stock Movements - Chevron Corp. (NYSE:CVX) shares rose approximately 5.8% following U.S. military actions in Venezuela, which boosted investor optimism about accessing Venezuelan oil resources [5] - Palantir Technologies Inc. (NASDAQ:PLTR) stock gained momentum amid speculation of its involvement in U.S. military operations in Venezuela, attracting attention from investors and analysts [6] - Nuclear energy stocks, including Centrus Energy Corp. (NYSE:LEU) and Energy Fuels Inc. (NYSE:UUUU), rallied after the Trump administration announced expanded federal support for domestic nuclear infrastructure, enhancing long-term demand prospects [7] Bearish Trends - Real estate and housing-linked stocks experienced significant sell-offs after President Trump announced plans to limit large institutional investors from purchasing single-family homes, impacting major players like Blackstone Inc. (NYSE:BX) and Invitation Homes Inc. (NASDAQ:INVH) [9] - U.S. defense stocks fell sharply after Trump ordered major defense contractors to halt dividends and share buybacks until they increased investments in production, affecting companies like Lockheed Martin Corp. (NYSE:LMT) and Northrop Grumman Corp. (NYSE:NOC) [10] - Aquestive Therapeutics Inc. (NASDAQ:AQST) shares dropped after the FDA flagged issues with its allergy drug application, raising concerns about potential delays in the approval process [11]

ARS Pharmaceuticals Inc. (NASDAQ:SPRY) stock rose Friday in reaction to a negative update for its rival Aquestive Therapeutics Inc. (NASDAQ:AQST).The U.S. Food and Drug Administration (FDA) identified deficiencies in Aquestive’s Anaphylm’s New Drug Application (NDA) that preclude discussion of labeling and post-marketing commitments at this time.The FDA stated that the notification does not reflect a final decision on the pending application, and the FDA’s review remains ongoing.In an investor note, William ...

To learn more about the Aquestive Therapeutics investigation, go to www.faruqilaw.com/AQST or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular ca ...

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Aquestive Therapeutics, Inc. (Nasdaq: AQST) for potential securities law violations. Investors who have lost money in their Aquestive Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/aqst. What is this all about? Shares of Aquestive Therapeutics fell more than 40% on January 9, 2026, after the company disclosed that th ...

Core Insights - The article discusses the potential approval of Anaphylm by Aquestive Therapeutics (AQST) and highlights possible catalysts leading up to the FDA PDUFA date [1]. Group 1: Company Overview - Aquestive Therapeutics is focused on developing innovative therapies and pharmaceuticals, particularly in the biotech sector [1]. - The company has a beneficial long position in its shares, indicating confidence in its future performance [2]. Group 2: Investment Strategy - The investment strategy revolves around identifying breakthrough therapies and potential acquisition targets within the healthcare sector [1]. - The investing group, Compounding Healthcare, offers various resources including model healthcare portfolios, newsletters, and a daily watchlist to support investors [1].

Group 1 - The article discusses the potential approval of Anaphylm by Aquestive Therapeutics (AQST) and highlights possible catalysts leading up to the FDA PDUFA date [1] - The author emphasizes a focus on innovative companies in the biotech sector that are developing breakthrough therapies and pharmaceuticals [1] - The investing group, Compounding Healthcare, offers features such as model healthcare portfolios, a weekly newsletter, and a daily watchlist for investors [1] Group 2 - The author has a beneficial long position in AQST shares, indicating a personal investment interest in the company [2] - The article expresses the author's opinions without any compensation from companies mentioned, ensuring an independent viewpoint [2] - Seeking Alpha clarifies that past performance does not guarantee future results and that the views expressed may not reflect the platform's overall stance [3]

Group 1 - The presentation is led by David Amsellem from Piper Sandler's Biopharma research team, focusing on the third quarter earnings cycle for Aquestive Therapeutics [1] - The senior leadership team of Aquestive Therapeutics is present, including the President and CEO, CFO, Chief Medical Officer, and other key executives [2] - The ACAAI meeting in Florida is highlighted as an important event where data related to Anaphylm will be presented in the coming days [2]

Core Insights - Aquestive Therapeutics (AQST) shares increased by 7.9% to $6.69, with a notable trading volume, contributing to a 27.1% gain over the past four weeks [1][2] Company Overview - The rise in stock price is attributed to positive expectations for Anaphylm, a key product candidate under FDA review for severe allergic reactions [2] - The USPTO granted two additional patents for Anaphylm, extending its protection until 2037 [2] Financial Performance - The company is projected to report a quarterly loss of $0.13 per share, unchanged from the previous year, with expected revenues of $13.36 million, a decrease of 1.3% year-over-year [3] - The consensus EPS estimate has remained stable over the last 30 days, indicating that stock price movements may not sustain without earnings estimate revisions [4] Industry Context - Aquestive Therapeutics holds a Zacks Rank of 3 (Hold), indicating a neutral outlook within the Zacks Medical - Drugs industry [5] - Comparatively, Madrigal (MDGL), another company in the same industry, experienced a 2% decline in its stock price, with a 1.6% return over the past month [5]

Core Viewpoint - Shares of Aquestive Therapeutics rose following the announcement of two new patents for its allergy therapy Anaphylm, which is currently under FDA review [4]. Company Summary - Aquestive Therapeutics is based in Warren, New Jersey, and operates in the biopharmaceutical sector [4]. - The newly issued patents cover the company's allergy therapy, Anaphylm, indicating potential for enhanced market position and intellectual property protection [4].

Core Insights - Several small-cap stocks experienced significant gains in after-hours trading due to corporate updates, clinical developments, and strategic shifts Company Summaries MEDIROM Healthcare Technologies Inc. (MRM) - Shares surged 282.8% to $5.55 after announcing plans to double the installation of its biometric authentication device "Orb" to 200 stores in collaboration with "World" [2] - Closed at $1.45 during regular trading, down 7.05%, with a trading volume of over 31.5 million shares [3] - The stock has a 52-week range of $0.34 to $5.30, highlighting the scale of its overnight move [3] Lexaria Bioscience Corp. (LEXX) - Shares rose 45.75% to $2.23 following renewed interest in its DehydraTECH drug delivery platform, which enhances GLP-1 drug delivery [4] - Closed at $1.53, up 7.75%, with a volume exceeding 7.5 million shares [5] - The stock's 52-week range is $0.775 to $3.392, with Thursday's close near the midpoint [5] Safety Shot, Inc. (SHOT) - Shares increased 12% to $0.28 after announcing a partnership with Monarq Asset Management to manage its BONK Holdings Treasury [6] - Closed at $0.25, down 9.06%, with a trading volume of over 15.4 million shares [7] - The stock has a 52-week range of $0.23 to $1.35, with the after-hours price near the lower end [7] Aquestive Therapeutics, Inc. (AQST) - Shares rose 11.41% to $5.86 following favorable regulatory news regarding its oral epinephrine candidate, Anaphylm [8] - Closed at $5.26, down 2.95%, with a volume of over 3.6 million shares [9] - The stock's 52-week range is $2.12 to $6.00, with the after-hours price near the upper end [9] Ovid Therapeutics Inc. (OVID) - Shares increased 4.26% to $1.47 after reaching a 52-week high during regular trading, driven by progress in its neurological pipeline [10] - Closed at $1.41, up 0.71%, with a trading volume of over 2.4 million shares [11] - The stock has a 52-week range of $0.2430 to $1.47, with Thursday's close at the top end of its recent performance band [11]